Biomarker study on pneumonitis in durvalumab maintenance therapy after chemoradiotherapy for stage III non-small cell lung cancer
Abstract Introduction The standard treatment for stage III non-small cell lung cancer (NSCLC) is platinum-based concurrent chemoradiotherapy (CCRT), followed by durvalumab (anti-programmed death ligand-1 antibody) maintenance therapy. Biomarkers related to immune-related pneumonitis during durvaluma...
Salvato in:
| Autori principali: | , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BMC
2025-12-01
|
| Serie: | BMC Cancer |
| Soggetti: | |
| Accesso online: | https://doi.org/10.1186/s12885-025-15467-0 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|